Celltrion, Inc. (KRX:068270)
South Korea
· Delayed Price · Currency is KRW 160,500
-700 (-0.43%)
At close: Jun 25, 2025, 3:30 PM KST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2014 - 2020 |
| Other | 750.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 25.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical Medicines | 6,177.68B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical Medicines Growth | 153.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Chemical Medicines | 523.71B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Chemical Medicines Growth | 3.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Segments | 6.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Segments Growth | 27.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Adjustments to | -3,045.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Adjustments to Growth | 386.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 750.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 25.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2014 - 2020 |
| Other | 150.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -100.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical Medicines Operating Income | 1,075.58B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical Medicines Operating Income Growth | 101.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Chemical Medicines Operating Income | 6.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Chemical Medicines Operating Income Growth | -74.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Segments Operating Income | 1.16B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Segments Operating Income Growth | 163.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Adjustments to Operating Income | -457.13B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Adjustments to Operating Income Growth | 503.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 150.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -100.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2014 - 2020 |
| Domestic | 1,560.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Domestic Growth | -15.77% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia | 195.01B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia Growth | 118.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 1,563.91B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America | 215.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Central and South America | 127.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|